My oncologist(s) and endocrinologist cite the breast cancer industry thinking that aromatase inhibitors can reduce the risk of recurrence by approximately 45%. With that current thinking, your risk of recurrence if you do not take them is approximately 6.5% if the OncotypeDX score is valid. (My doctors think it is.) I don't know if that helps but gives you a "if I don't take aromatase inhiibitors" framework. Oncotype's customer support is very good and can describe more.